c-LEcta Signs Sales and Distribution Agreement with VWR, part of Avantor, for Europe
The Avantor company has signed sales and distribution agreements for c-LEcta’s DENARASE
VWR, part of Avantor, and the German biotechnology specialist c-LEcta GmbH (c-LEcta), announce the signing of a sales and distribution agreement for c-LEcta’s DENARASE® , a high-quality nuclease for the removal of all forms of DNA and RNA in bio pharmaceutical processes. Based on this agreement, DENARASE® will now be available through vwr.com and all other regular VWR sales channels in Europe.
VWR is a leading global provider of product and service solutions to laboratory and production customers.
At a glance, the benefits of DENARASE® are:
- Full compliance with cGMP
- Animal product free production
- Endotoxin-free production strain
- High purity & activity
DENARASE® is a highly active nuclease that is used to quantitatively eliminate interfering host cell DNA and RNA from fermentation batches, e.g. during the production of vaccines and bio pharmaceuticals. Therefore, it is the first choice for pharmaceutical manufacturers to optimize their process efficiencies and improve product recovery rates.
DENARASE® is manufactured using a patent protected production process based on the recombinant expression in an endotoxin-free Bacillus sp. production host. The manufacturing process is free of products from animal origin and antibiotics and in full compliance with cGMP requirements.